321 related articles for article (PubMed ID: 29901113)
1. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.
Lang L; Shay C; Zhao X; Teng Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):112. PubMed ID: 28830537
[TBL] [Abstract][Full Text] [Related]
4. Salirasib in the treatment of pancreatic cancer.
Bustinza-Linares E; Kurzrock R; Tsimberidou AM
Future Oncol; 2010 Jun; 6(6):885-91. PubMed ID: 20528225
[TBL] [Abstract][Full Text] [Related]
5. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Zundelevich A; Elad-Sfadia G; Haklai R; Kloog Y
Mol Cancer Ther; 2007 Jun; 6(6):1765-73. PubMed ID: 17541036
[TBL] [Abstract][Full Text] [Related]
6. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
[TBL] [Abstract][Full Text] [Related]
7. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Levy R; Grafi-Cohen M; Kraiem Z; Kloog Y
Mol Cancer Ther; 2010 Aug; 9(8):2208-19. PubMed ID: 20682656
[TBL] [Abstract][Full Text] [Related]
9. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
Zhao Y; Fan D; Ru B; Cheng KW; Hu S; Zhang J; Li ET; Wang M
Eur J Cancer; 2016 Nov; 68():38-50. PubMed ID: 27710830
[TBL] [Abstract][Full Text] [Related]
10. Ras inhibitors display an anti-metastatic effect by downregulation of lysyl oxidase through inhibition of the Ras-PI3K-Akt-HIF-1α pathway.
Yoshikawa Y; Takano O; Kato I; Takahashi Y; Shima F; Kataoka T
Cancer Lett; 2017 Dec; 410():82-91. PubMed ID: 28951129
[TBL] [Abstract][Full Text] [Related]
11. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
[TBL] [Abstract][Full Text] [Related]
13. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
14. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Makovski V; Haklai R; Kloog Y
Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
[TBL] [Abstract][Full Text] [Related]
15. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
16. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.
Mashiach-Farkash E; Rak R; Elad-Sfadia G; Haklai R; Carmeli S; Kloog Y; Wolfson HJ
Oncotarget; 2012 Jun; 3(6):629-39. PubMed ID: 22776759
[TBL] [Abstract][Full Text] [Related]
17. The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth.
Hameiri-Grossman M; Porat-Klein A; Yaniv I; Ash S; Cohen IJ; Kodman Y; Haklai R; Elad-Sfadia G; Kloog Y; Chepurko E; Feinmesser M; Issakov J; Sher O; Luria D; Kollender Y; Weizman A; Avigad S
Oncotarget; 2015 Oct; 6(32):33834-48. PubMed ID: 26393682
[TBL] [Abstract][Full Text] [Related]
18. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
19. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
20. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]